FTSE 100 news / Companies and sectors / GSK / GSK reported to be buying Nuvalent

GSK reported to be buying Nuvalent

+3.5 positive

A report asks why GSK is buying a Boston-based oncology company whose stock surged premarket.

4 headlines from 3 outlets, from 2 October 2026 to 7 October 2026. The story's tone is the average of its headlines' own scores.

How each outlet covered it

Average tone of each outlet's headlines in this story. One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Outlet	Headlines	Tone
Kalkine Media	2	+5.2
stocktwits.com	1	+7.5
AD HOC NEWS	1	−3.7

Day by day

Wednesday 7 October 2026 1 headline

Kalkine asks why GSK is in focus after the Nuvalent agreement.

+5.3 Why Is GSK (LSE:GSK) Stock Back In Focus This Week After The Nuvalent Agreement? Kalkine Media
Stock in focus after Nuvalent agreement

Tuesday 6 October 2026 1 headline

Kalkine asks whether the Nuvalent acquisition can drive growth.

+5.0 Can FTSE 100 Drugmaker (LSE:GSK) Turn Its Nuvalent Acquisition Into A Fresh Growth Engine After This Week's Deal News? Kalkine Media
Nuvalent acquisition viewed as possible growth engine

Monday 5 October 2026 1 headline

GSK stock trades after Nuvalent deal risks emerged.

−3.7 GSK stock trades at GBp 1,779.50 after Nuvalent deal risks emerge AD HOC NEWS
Share price story highlights risks emerging around the Nuvalent deal.

Friday 2 October 2026 1 headline

A report asks why GSK is buying a Boston-based oncology company whose stock surged premarket.

+7.5 NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? stocktwits.com
Reported acquisition of oncology company Nuvalent, expanding cancer pipeline.

GSK: all news analysis · Sector · FTSE 100 news